Hikma Pharmaceuticals Stock

GBP19.39

1.27% day before yesterday

London, Aug 01, 05:35 pm CET

ISIN

GB00B0LCW083

Symbol

HIK

Index

FTSE 100, STOXX Europe 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

Hikma Pharmaceuticals Stock price

GBP19.39

-0.25 1.27% 5Y

London, Closing price Fri, Aug 01 2025

-0.25 1.27%

ISIN

GB00B0LCW083

Symbol

HIK

Index

FTSE 100, STOXX Europe 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

GBP4.3b

Enterprise Value

GBP5.2b

Net debt

GBP823.0m

Cash

GBP160.4m

Shares outstanding

221.9m

Valuation (TTM | estimate)

P/E

16.0 | 10.9

P/S

1.8 | 1.7

EV/Sales

2.2 | 2.0

EV/FCF

20.8

P/B

2.5

Dividends

DPS

GBP0.61

Yield 1Y | 5Y

3.2% | 2.4%

Growth 1Y | 5Y

24.3% | 12.6%

Payout 1Y | 3Y

50.8% | 61.6%

Increased

19 Years

Financials (TTM | estimate)

Revenue

GBP2.4b | GBP2.6b

EBITDA

GBP542.9m | GBP677.9m

EBIT

GBP473.6m | GBP570.5m

Net Income

GBP270.3m | GBP394.5m

Free Cash Flow

GBP247.7m

Growth (TTM | estimate)

Revenue

9.8% | 8.2%

EBITDA

1.5% | 24.9%

EBIT

1.1% | 20.5%

Net Income

88.9% | 46.0%

Free Cash Flow

-18.6%

Financial Health

Equity Ratio

45.0%

Return on Equity

15.5%

ROCE

19.9%

ROIC

13.0%

Debt/Equity

0.6

EPS

GBP1.2

FCF per Share

GBP1.1

Short interest

109.0%

Employees

10k

Rev per Employee

GBP250.0k

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Get Started for Free Today

Hikma Pharmaceuticals Stock Analysis

Unlock Scores for Free

??

20 Analysts have issued a Hikma Pharmaceuticals forecast:

16x Buy

80%

4x Hold

20%

More details on Analyst Estimates Including Price Targets

20 Analysts have issued a Hikma Pharmaceuticals forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Hikma Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	2,376 2,376	10% 10% 100%
- Direct Costs	1,286 1,286	16% 16% 54%
Gross Profit	1,090 1,090	3% 3% 46%
- Selling and Administrative Expenses	428 428	4% 4% 18%
- Research and Development Expense	106 106	5% 5% 4%
EBITDA	543 543	2% 2% 23%
- Depreciation and Amortization	69 69	5% 5% 3%
EBIT (Operating Income) EBIT	474 474	1% 1% 20%
Net Profit	270 270	89% 89% 11%

In millions GBP.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Riad Mishlawi
Employees	9,500
Founded	1978
Website	www.hikma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now